

Fig. 1

Phase	Screening		Study treatment						Follow-up Visits					EOS Visit ^a	
Day	D-28 to D-2	D-1	D1	D2	D3	D4	D5	D6	D8	D15 ±1	D29 ±2	D57 ±3	D71 ±3		
Informed consent	X														
Institutionalization		X													
Discharge				X											
Visit at clinical site	X				X	X	X	X	X	X	X	X	X		
Inclusion/exclusion criteria	X	X													
Demography	X														
Medical/surgical history	X	X													
Prior/concomitant medications	<	-	-	-	-	-	-	-	-	-	-	-	-	>	
Randomization			X ^b												
Study treatment administration															
SAR443765 or placebo			X												
NIMP administration															
Bronchodilator	X ^c	X							X	X	X	X			
Asthma background treatment ^d	<	-	-	-	-	-	-	-	-	-	-	-	-	>	
Safety															
Physical examination ^e	X	X					X							X	
Height	X														
Body weight (kg)	X	X									X			X	
Archival blood sample			X ^f												
Serology tests (HBs Ag, anti-HBc Ab, anti-HCV, anti-HIV1 Ab and anti-HIV2 Ab)	X														
Urine drug screen, alcohol tests ^g	X	X													
Vital signs ^h	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
12-lead ECG ^h	X	X	X	X	X	X	X	X	X		X	X	X	X	
Tympanic temperature	X	X	X	X	X	X	X								

Fig. 1 (continued)


Phase	Screening		Study treatment					Follow-up Visits					EOS Visit ^a		
Day	D-28 to D-2	D-1	D1	D2	D3	D4	D5	D6	D8	D15 ±1	D29 ±2	D57 ±3	D71 ±3		
Hematology, biochemistry, urinalysis, coagulation ^f	X	X		X		X			X	X	X	X	X		
High-sensitivity cardiac troponin ^g		X		X		X			X	X	X	X	X		
β-HCG test ^k	X	X									X	X	X		
FSH ^l	X														
SARS-CoV-2 testing		X ^m							X ⁿ	X ⁿ	X ⁿ	X ⁿ			
Local site reaction			X	X	X	X	X								
Adverse event collection	<	-	-	-	-	-	-	-	-	-	-	-	-	>	
Antidrug antibodies (serum)			X ^o							X	X			X	
Archived PBMC collection for possible exploratory measurement of T cell responses			X ^o							X				X	
Pharmacokinetics															
SAR443765 PK serum samples			S00-S03	S04	S05	S06	S07	S08	S09	S10	S12	S14	S15		
Pharmacogenomics															
Archival DNA															
Pharmacogenomic sample			X ^o												
Blood/nasal brushing samples for bulk transcriptomic analyses			X ^o								X				
Blood (PBMC and PBL) nasal brushing samples for potential exploratory single cell transcriptomic analyses ^{p, q} , if feasible			X ^o								X				
Pharmacodynamics															
Fraction of exhaled nitric oxide (FeNO) ^{q, r}	X	X							X	X	X	X			

Fig. 1 (continued)

Phase	Screening		Study treatment						Follow-up Visits				EOS Visit ^a	
	D-28 to D-2	D-1	D1	D2	D3	D4	D5	D6	D8	D15 ±1	D29 ±2	D57 ±3	D71 ±3	
Day		X ^t												
PD respiratory evaluation by impulse oscillometry (pre-BD)q, r		X ^t							X	X	X	X		
PD respiratory evaluation by impulse oscillometry (post-BD)q, r, s		X ^t							X	X	X	X		
Spirometry (FEV1) (pre-BD)q, r	X ^c	X ^t							X	X	X	X		
Spirometry (FEV1) (post-BD)q, r, s	X ^c	X ^t							X	X	X	X		
Selected biomarkers of the IL-13 and TSLP pathway (plasma CCL26, serum TARC, IL-5 and IgE, and eosinophil count)			X ^o						X	X	X	X	X	
Total target TSLP (serum)		X	X	X	X	X			X	X	X	X	X	
Total target IL-13 (serum)		X	X	X	X	X			X	X	X	X	X	


4/22

Fig. 2



5/22

Fig. 3



6/22

Fig. 4






Fig. 5




8/22

Fig. 6




9/22

Fig. 7




10/22

Fig. 8



11/22

Fig. 9



12/22

Fig. 9 (continued)




Fig. 10

R5-20





Fig. 10 (continued)



15/22

Fig. 11

AX

Change from baseline - Mean($\pm$ SEM))




Fig. 11 (continued)




Fig. 12




Fig. 13




Fig. 14





Fig. 15

PBL – SAR443765 and Placebo



PBL – SAR443765 only




Fig. 16




Fig. 17

